Contributions of HarmReductionHen

Contributions by HarmReductionHen, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 2,666 edits includes activity predating the current log.

1. 06:47, 22 Jun 2026 (diff | hist) Sharps disposal 17,901 ±0 move a stray full stop inside the reference
2. 03:45, 18 Jun 2026 (diff | hist) Good manufacturing practice 5,123 ±0 m add the cross-link to the legal-status-by-jurisdiction list
3. 14:55, 4 Jun 2026 (diff | hist) Talk:Sharps disposal 1,033 +199 /* Register: §Improvised containers reads as instruction */ reply
4. 14:20, 14 Apr 2026 (diff | hist) Talk:Beyond-use date 1,159 +269 /* Community dating practice: describe or omit? */ reply
5. 13:20, 16 Feb 2026 (diff | hist) Talk:Prior authorisation 611 +105 /* Migration to unregulated supply */ reply
6. 15:09, 14 Feb 2026 (diff | hist) Solid-phase peptide synthesis 5,359 ±0 expand §Scale and its limits
7. 06:09, 9 Feb 2026 (diff | hist) Contraindications of incretin therapy 4,993 ±0 clarify that the effect resolved on discontinuation in the cited series
8. 08:30, 24 Jan 2026 (diff | hist) Talk:Multi-dose vial 1,518 +239 /* Does adding bacteriostatic water make a preparation preserved? */ reply
9. 09:40, 13 Jan 2026 (diff | hist) Talk:Peptide harm reduction 400 +170 /* Where the line sits */ new section
10. 08:47, 9 Dec 2025 (diff | hist) Talk:Temperature excursion 1,729 +189 /* Is a community-reported stability observation usable evidence at all? */ reply
11. 09:31, 5 Dec 2025 (diff | hist) Talk:Temperature excursion 1,096 +338 /* Is a community-reported stability observation usable evidence at all? */ reply
12. 05:15, 21 Nov 2025 (diff | hist) Prior authorisation 4,216 ±0 add the manufacturer assistance programme with its eligibility criterion
13. 00:11, 7 Nov 2025 (diff | hist) Insulin secretion 6,940 ±0 attribute the gastric-emptying effect to the study that measured it
14. 04:32, 11 Oct 2025 (diff | hist) Cost per milligram 4,125 +98 m rm a duplicated category
15. 08:34, 31 Aug 2025 (diff | hist) Cost per milligram 4,027 ±0 add the citation for the discontinuation-on-cost finding
16. 20:32, 21 Aug 2025 (diff | hist) Prescribing information 4,506 ±0 correct the population figure — the source gives eligible, not treated
17. 19:35, 28 May 2025 (diff | hist) Prescribing information 4,364 +40 give the cost per unit of effect rather than only the cost
18. 09:36, 6 May 2025 (diff | hist) Peptide harm reduction 3,975 +507 fix a dangling clause
19. 21:22, 18 Mar 2025 (diff | hist) Nantong Guangyuan Chemical 9,618 +623 add the note that self-published material is usable only for what it states about itself
20. 19:31, 2 Jan 2025 (diff | hist) Cost per milligram 1,509 +489 state the exchange rate and its date
21. 01:09, 30 Nov 2024 (diff | hist) Peptide harm reduction 1,258 +1,258 N create article — access and cost stub
22. 05:02, 23 Nov 2024 (diff | hist) Drug master file 2,196 +407 m clarify that a business licence is not a manufacturing authorisation
23. 17:01, 3 Oct 2024 (diff | hist) Certificate of analysis 3,722 +236 convert a hard-coded date to the house format
24. 09:00, 8 Sep 2024 (diff | hist) Prescribing information 1,931 +1,931 N new article: access and cost, expansion welcome